Positive data from LEO Pharma’s delgocitinib cream trial
Study involves the treatment of adults with moderate-to-severe chronic hand eczema
Read More
Tag: LEO Pharma
LEO Pharma reveal positive results from delgocitinib research
Phase 3 clinical trial focuses on adults with moderate-to-severe chronic hand eczema
Read More
LEO Pharma launches ‘AD Days Around the World’
Events will raise awareness around the impact of atopic dermatitis across cultures
Read More
NICE recommend’s use of Leo Pharma’s Adtralza
The therapy is for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment
Read More
EU regulators agree to review LEO’s dermatitis drug
The drug targets a key driver of the underlying inflammation in the condition
Read More
LEO issues Picato recall
Last September, the EMA’s Pharmacovigilance Risk Assessment Committee announced a review of data on skin cancer in patients using the drug.
Read More
LEO Pharma completes Bayer prescription dermatology business acquisition
Under the terms of the agreement, LEO Pharma has now acquired the global product rights for Bayer’s global prescription dermatology business with the exception of Afghanistan and Pakistan.
Read More
Psoriasis patients get NHS access to LEO Pharma’s Kyntheum
Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis.
Read More
Plaque psoriasis patients to get NHS access to LEO’s Kyntheum
Patients with severe plaque psoriasis are a step closer to getting NHS funded access to LEO Pharma’s Kyntheum, after cost regulators published final draft guidelines backing the drug.
Read More
EU approves LEO Pharma’s psoriasis biologic
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.
Read More
FDA nod for Valeant’s psoriasis drug
The US Food and Drug Administration has issued a green light for Valeant to market Siliq as a treatment for adults with moderate-to-severe plaque psoriasis, but with a boxed warning on suicide and a restricted prescriber programme.
Read More
SMC green light for LEO’s Enstilar
GPs and dermatology clinicians in Scotland are now authorised to prescribe LEO Pharma’s Enstilar on the NHS for the management of all severities of plaque psoriasis in adult patients, after it was endorsed by the Scottish Medicines Consortium.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
